Gilead, Mylan expand license deal for HIV/AIDS medicines
Posted on July 9th, 2011
Mylan Inc. today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan’s Matrix Laboratories Limited. Matrix has licensed the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, if and when they receive regulatory approval. The Gilead products, which are currently in late-stage clinical development, include: Elvitegravir, an investigational integrase inhibitor; Cobicistat, an investigational antiretroviral boosting agent; and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines.
Mylan President Heather Bresch commented: “Every patient living with HIV/AIDS has a right to treatment. Matrix has made a significant contribution to dramatically lowering the cost of HIV/AIDS medicines, and we are now focused on expanding access to high-quality treatment to more people who need it. We are pleased to expand our collaboration with Gilead as it will enable more individuals living with HIV/AIDS in resource-limited countries to access the newest innovative medicines.”
Similar Posts:
- Tax Deduction For Haiti Relief Bill Signed Into Law
- How Health Savings Accounts Contributions Work
- Considerable Increase in Health Savings Account Clients Reported by Fidelity Investments
- The President’s Review of Intelligence and Aviation Security
- Facts about critical illness cover
Tags: License, License Deal
Filed under Health Insurance |